Login / Signup

A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal.

Ryan FeldmanBrian AutryJoanna DukesThomas LofyGina MarchettiAmber PattNicole BattermanJillian Theobald
Published in: Clinical toxicology (Philadelphia, Pa.) (2023)
Phenibut withdrawal appears to have a range of severity. It is important to recognize that patients undergoing phenibut abstinence may have progressive symptom worsening during early withdrawal. All published cases of abrupt phenibut abstinence were admitted inpatients for symptom management. Benzodiazepines or barbiturates with adjunctive baclofen appear to be the most commonly used drugs for moderate to severe withdrawal. Outpatient management via slow phenibut tapers with or without adjunctive gamma-aminobutyric acid agonist therapy may be successful. However, there is no standard treatment, and consultation with experts (e.g., toxicologists, addiction specialists) experienced in managing withdrawal syndromes is recommended. Significant study is warranted to develop methods of triaging phenibut withdrawal (e.g., severity scoring, inpatient versus outpatient management) and creating optimal treatment regimens.
Keyphrases
  • patients undergoing
  • palliative care
  • multiple sclerosis
  • smoking cessation
  • systematic review
  • risk factors
  • early onset
  • combination therapy
  • replacement therapy
  • cell therapy